Equity Profile

EWTX

Edgewise Therapeutics, Inc.

Health CarePharmaceuticals$4.4B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:00 AM EDT

Edgewise Therapeutics Misses on Revenue, Stock Down 3.81%

Metric	Actual	Expected	Surprise
EPS	$-0.46	$-0.48	+8.18%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Edgewise Therapeutics Misses on Revenue, Stock Down 3.81%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.46	$-0.48	+8.18%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.

What It Means

Edgewise Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the lack of revenue and guidance may have contributed to the stock's decline of 3.81%. Investors will likely be looking for more information in future reports to assess the company's trajectory.

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

$-0.48

Revenue

While no revenue is expected this quarter, any commentary on future revenue generation will be crucial for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as new treatments and technologies emerge.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

In the last quarter, Edgewise reported an EPS of $-0.47, which was worse than the expected $-0.43. The stock reacted negatively, dropping 1.53% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Edgewise to report a loss of $-0.48 per share this quarter, with no revenue projected. Investors are keen to see if the company can narrow its losses or provide positive guidance.

Bull Case

If Edgewise can beat earnings expectations and provide positive commentary on future drug development, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses expectations again or provides no clear path to revenue generation, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.48

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

Revenue

$0M

While no revenue is expected this quarter, any commentary on future revenue generation will be crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.48?

A smaller loss than expected could indicate improving operational efficiency and boost investor sentiment.

What is the company's outlook for future revenue generation?

Any guidance on potential revenue streams will be critical for assessing the company's growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic, expecting a loss of $-0.48, but the company's recent trend of narrowing losses suggests it could outperform this expectation.

Supporting Evidence

Edgewise has consistently surprised on the upside in 75% of the last eight quarters.

The options market is pricing a larger move than historically realized, indicating potential for a surprise.

Key Risk

If the EPS comes in better than $-0.48, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Edgewise can show signs of narrowing losses and provide a clearer path to revenue.

Bull Confirmed If

A reported EPS loss of less than $-0.48 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.48 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

67.8%

Calls (24K)P/C Ratio: 0.78Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 11 (36%)

This setup has occurred 30 times across Health Care in the last 2 years. 7 of 11 (64%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.5%, with a raw directional average of +3.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests a potential average one-day move of +1.69%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty around future guidance.

Miss

Should the company miss expectations, history suggests an average one-day move of -1.99%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug development timelines and potential revenue sources.
2Management's commentary on operational efficiencies and cost management.
3Insights into market conditions affecting the pharmaceutical sector.
4Details on any partnerships or collaborations that could drive future growth.
5Guidance on expected timelines for product launches or clinical trial results.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Hess Midstream LP

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

$-0.48

Revenue

While no revenue is expected this quarter, any commentary on future revenue generation will be crucial for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

In the last quarter, Edgewise reported an EPS of $-0.47, which was worse than the expected $-0.43. The stock reacted negatively, dropping 1.53% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Edgewise to report a loss of $-0.48 per share this quarter, with no revenue projected. Investors are keen to see if the company can narrow its losses or provide positive guidance.

Bull Case

If Edgewise can beat earnings expectations and provide positive commentary on future drug development, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses expectations again or provides no clear path to revenue generation, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.48

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

Revenue

$0M

While no revenue is expected this quarter, any commentary on future revenue generation will be crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.48?

A smaller loss than expected could indicate improving operational efficiency and boost investor sentiment.

What is the company's outlook for future revenue generation?

Any guidance on potential revenue streams will be critical for assessing the company's growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic, expecting a loss of $-0.48, but the company's recent trend of narrowing losses suggests it could outperform this expectation.

Supporting Evidence

Edgewise has consistently surprised on the upside in 75% of the last eight quarters.

The options market is pricing a larger move than historically realized, indicating potential for a surprise.

Key Risk

If the EPS comes in better than $-0.48, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Edgewise can show signs of narrowing losses and provide a clearer path to revenue.

Bull Confirmed If

A reported EPS loss of less than $-0.48 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.48 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

67.8%

Calls (24K)P/C Ratio: 0.78Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 11 (36%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests a potential average one-day move of +1.69%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty around future guidance.

Miss

Should the company miss expectations, history suggests an average one-day move of -1.99%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug development timelines and potential revenue sources.
2Management's commentary on operational efficiencies and cost management.
3Insights into market conditions affecting the pharmaceutical sector.
4Details on any partnerships or collaborations that could drive future growth.
5Guidance on expected timelines for product launches or clinical trial results.